{"id":36909,"date":"2025-11-10T13:42:30","date_gmt":"2025-11-10T13:42:30","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=36909"},"modified":"2025-11-10T13:53:16","modified_gmt":"2025-11-10T13:53:16","slug":"inbrain-partners-with-microsoft-to-develop-ai-driven-brain-computer-interface-therapies","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/pl\/inbrain-partners-with-microsoft-to-develop-ai-driven-brain-computer-interface-therapies\/","title":{"rendered":"INBRAIN Partners with Microsoft to Develop AI-Driven Brain-Computer Interface Therapies"},"content":{"rendered":"<p class=\"wp-block-paragraph translation-block\">Spain-based <a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/inbrain-neuroelectronics\/\" target=\"_blank\" rel=\"noreferrer noopener\">INBRAIN Neuroelectronics<\/a> has announced a collaboration with Microsoft to apply advanced artificial intelligence to its next-generation brain-computer interface (BCI) therapeutics. The partnership aims to harness Microsoft\u2019s Azure AI and data infrastructure to enhance INBRAIN\u2019s graphene-based neural platform, enabling real-time, adaptive interaction with individual patient brain signals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration focuses on developing \u201cagentic AI\u201d \u2014 autonomous AI systems capable of making real-time decisions based on continuous neural data. This approach could redefine how neurological disorders such as Parkinson\u2019s disease, epilepsy, and psychiatric or memory conditions are monitored and treated. By learning directly from neural feedback, the system could deliver highly personalized, closed-loop therapies tailored to each patient\u2019s brain activity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cOur vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and AI,\u201d said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. \u201cBy collaborating with Microsoft, we\u2019re combining our precision graphene neural technology with one of the world\u2019s most powerful AI ecosystems. This partnership brings us closer to a future where brain-computer interfaces don\u2019t just decode or modulate, but truly understand and respond to the nervous system in real time.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clare Barclay, President of Enterprise and Industry, EMEA at Microsoft, described the collaboration as a milestone in the evolution of AI. \u201cINBRAIN\u2019s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the data foundation and computational infrastructure that will help accelerate their mission to improve neurological health worldwide,\u201d she said.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">INBRAIN\u2019s neural technology is built on graphene, a highly conductive and biocompatible material that enables precise neural decoding and stimulation. By combining this with Microsoft\u2019s AI capabilities, the companies aim to create a new class of brain-computer interface therapeutics that can autonomously analyze and modulate neural circuits. The partnership also reflects a shared commitment to responsible innovation, data security, and patient privacy in advancing neurotechnology for clinical use.<\/p>","protected":false},"excerpt":{"rendered":"<p>INBRAIN Neuroelectronics has teamed up with Microsoft to integrate agentic AI into its graphene-based brain-computer interface technologies, aiming to advance precision neurology and personalized neurotherapeutics.<\/p>","protected":false},"author":2,"featured_media":36910,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[488,681,6,10],"tags":[802],"class_list":["post-36909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","category-care-therapy","category-europe","category-strategic-development","tag-bci"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/posts\/36909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/comments?post=36909"}],"version-history":[{"count":1,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/posts\/36909\/revisions"}],"predecessor-version":[{"id":36911,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/posts\/36909\/revisions\/36911"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/media\/36910"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/media?parent=36909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/categories?post=36909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/pl\/wp-json\/wp\/v2\/tags?post=36909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}